Tag: the war on (some) drugs

White House Announces Withdrawal Of Trump’s Drug Czar Nominee Who Embraced Medical Marijuana

The White House has notified Congress that President Donald Trump’s nominee to lead the Office of National Drug Control Policy (ONDCP)—who has publicly backed medical marijuana access—is being withdrawn.

About three months after Trump picked Sara Carter to become the next White House drug czar, the administration told lawmakers on Thursday that she’s no longer up for consideration for the position.

It’s currently unclear whether Carter withdrew from consideration herself or if it was a decision made by the president. Marijuana Moment reached out to the White House for comment, but a representative did not respond by the time of publication.

The notice published in the Congressional Record about the withdrawal of the nomination reads:

“WITHDRAWAL

Executive Message transmitted by the President to the Senate on June 26, 2025 withdrawing from further Senate consideration the following nomination:

SARA CARTER, OF TEXAS, TO BE DIRECTOR OF NATIONAL DRUG CONTROL POLICY, VICE RAHUL GUPTA, RESIGNED, WHICH WAS SENT TO THE SENATE ON MAY 6, 2025.”

There was some enthusiasm about Carter’s nomination among cannabis reform advocates, as she’s previously called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t have a “problem” with legalization, even if she might not personally agree with the policy.

Given the role of ONDCP director in setting and carrying out the administrative agenda on drug policy issues, the fact that Carter went on the record enthusiastically endorsing medical cannabis represented a welcome development for advocates amid Senate confirmations of other officials with a mixed bag of marijuana records.

Under longstanding federal statute, the drug czar is prohibited from endorsing the legalization of Schedule I drugs in the Controlled Substances Act (CSA), including marijuana. However, Democratic congressional lawmakers in April filed a bill that would remove that restriction.

Keep reading

Treasury Sanctions 3 Mexican Financial Institutions For Aiding Cartels In Fentanyl Trade; Sheinbaum Denies

Mexican President Sheinbaum has commented on the sanctions, denying any fraud and claiming the Mexican banking system is ‘sound’:

  • *SHEINBAUM: NO EVIDENCE OF MONEY LAUNDERING IN MEXICAN BANKS
  • *SHEINBAUM SAYS MEXICO ONLY FOUND ADMINISTRATIVE FLAWS IN BANKS
  • *SHEINBAUM: MEXICO ASKED US TREASURY MONEY LAUNDERING EVIDENCE
  • *SHEINBAUM: MEXICAN FINANCIAL SYSTEM SOUND, ACCUSED FIRMS SMALL
  • *MEXICO TRANSFERS TO CHINA COS ‘NOT MONEY LAUNDERING’: SHEINBAUM

Just a coincidence?

As Naveen Athrappully detailed earlier via The Epoch Times, The Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN) sanctioned three financial institutions based in Mexico for allegedly laundering money for cartels involved in the illegal trade of fentanyl, the Treasury said in a June 25 statement. The institutions are CIBanco S.A., Intercam Banco S.A., and Vector Casa de Bolsa S.A. de C.V.

CIBanco and Intercam are commercial banks with assets worth more than $7 billion and $4 billion, respectively. Vector is a brokerage company managing almost $11 billion in assets.

FinCEN has determined that the entities launder money in connection with illicit opioid trafficking, and have “collectively played a longstanding and vital role in laundering millions of dollars on behalf of Mexico-based cartels and facilitating payments for the procurement of precursor chemicals needed to produce fentanyl,” the statement said.

CIBanco facilitated illicit opioid trafficking by Mexican cartels such as Jalisco New Generation Cartel (CJNG), Beltran-Leyva Cartel, and Gulf Cartel. Intercam was linked to CJNG, and Vector with the Sinaloa Cartel and Gulf Cartel, said the statement.

FinCEN said that between 2021 and 2024, CIBanco processed more than $2.1 million in payments from Mexico-based companies to entities in China that shipped precursor chemicals to Mexico. Intercam processed over $1.5 million during the same period.

As for Vector, the institution processed more than $1 million between 2018 and 2023.

The sanctions prohibit financial institutions in the United States from engaging in the transmission of funds from or to CIBanco, Intercam, or Vector. The prohibition also applies to any account or convertible virtual currency address administered by the three institutions.

Keep reading

Nebraska Medical Marijuana Regulators Approve Emergency Rules Banning Flower Access For Patients

The Nebraska Medical Cannabis Commission on Thursday approved emergency regulations to begin accepting medical cannabis applications as soon as Gov. Jim Pillen (R) gives his final green light.

State law requires him to do so by Tuesday.

The emergency regulations, unveiled for the first time minutes before the 10 a.m. meeting, largely mirror a legislative proposal that lawmakers stalled on last month. The regulations would take effect for up to 90 days, pending Pillen’s approval. The two medical cannabis-related laws that voters approved mandate that applications must start being accepted no later than July 1.

Commissioner Lorelle Mueting of Gretna, an addiction prevention specialist through Heartland Family Service, affirmed that commissioners want public feedback on the emergency regulations through July 15, to inform future, formal regulations.

Public comments may be submitted to lcc.frontdesk@nebraska.gov, the repository for the Nebraska Liquor Control Commission, which will forward the messages onto the state’s new Medical Cannabis Commission.

“The input that the public provides on these emergency regulations will help us immediately begin drafting the regular regulations,” Mueting said Thursday.

Keep reading

FDA Plan To Include Hemp-Derived Cannabinoids In Federal Adverse Health Event Reporting System Goes To White House For Approval

The U.S. Food and Drug Administration (FDA) is moving forward with a proposal that aims to better track the health impacts of hemp-derived cannabinoid products by adding CBD and other hemp-derived cannabinoids as selectable options on federal documents used by healthcare professionals, patients and consumers to report adverse events.

Initially unveiled in January, the proposal would revise the “Product Type” field of FDA safety reporting documents to include a selection for “Cannabinoid Hemp Products (such as products containing CBD).” An initial round of comments was open until mid-March.

In a post published in the Federal Register this week, FDA announced that the “proposed collection of information” has now been submitted to the White House Office of Management and Budget (OMB) “for review and clearance.”

The new filing says that two comments were received in the initial round of public feedback supporting the addition of a “cannabinoid hemp product” category “but encouraged FDA to include additional categories as well that would allow for specific data as it pertained to a wider variety of individual products.” A third called for changes to make entries easier by respondents.

“FDA appreciates each comment and although we continue to modify applicable forms to increase the utility of the information collection as our limited resources allow,” the agency said, “we are proposing no other modifications at this time.”

An additional round of feedback is now being accepted on the submission of the information, with comments due by July 25.

The move—designed to more actively gather information about adverse health effects that might be linked to hemp-derived products—comes amid a number of other CBD-focused actions at the federal level and state levels.

Earlier this week, for example, a powerful House committee approved a spending bill containing provisions that hemp stakeholders say would devastate the industry, prohibiting most consumable cannabinoid products that were federally legalized during the first Trump administration.

The House Appropriations Committee passed the agriculture appropriations legislation in a 35-27 vote on Monday. It now heads to the Rules Committee to be prepared for floor consideration.

While the panel adopted a manager’s amendment to a report attached to the bill earlier this month that provided clarifying language stating that members did not intend to prohibit non-intoxicating cannabinoid products with “trace or insignificant amounts of THC,” the underlying bill went unchanged, despite the industry’s concerns about the proposal.

Keep reading

Just one single dose of ‘magic mushrooms’ could relieve depression for 5 years, researchers find

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, followed up with patients who had been diagnosed with clinical depression — also known as major depressive disorder (MDD) — and had participated in a previous psilocybin treatment study in 2020.

“Most people who participated in our trial reported improvements in depression symptom intensity or in the ways in which they experienced depression in their life, lasting up to five years after the trial,” study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Fox News Digital.

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that the outcome speaks to the “exciting” potential of psilocybin and other psychedelic-based treatments in treating MDD and other mental health conditions.

“The results of the study are certainly very encouraging,” said Drysdale, who was not involved in the study.

Earlier studies pointed toward the possibility of psilocybin as a potential antidepressant, prompting researchers to conduct the first-ever randomized clinical trial.

Keep reading

Nebraska Medical Cannabis Commission Proposal Will ‘Destroy Patient Access,’ Advocates Say

It’s unclear what requirements the state commission to regulate medical cannabis in Nebraska might enact to license such operations by this fall, ahead of a deadline next week for detailing the criteria for applications.

The Nebraska Medical Cannabis Commission has until July 1 to write licensing criteria under state law. But as commissioners gear up for their next meeting Thursday, the first with all five commissioners, they have indicated they will consider adopting draft or emergency criteria to accept or deny licensing applications after July 1.

Licensing must begin by October 1, the same time any other requirements for medical cannabis must be enacted, according to a pair of laws that voters overwhelmingly approved in a pair of November ballot measures.

However, with just hours until the next commission meeting, there is no specific indication of what criteria the board will consider.

Also on the agenda is a legal “memorandum of agreement” to help with future rulemaking involving the Nebraska Department of Health and Human Services (DHHS) and Gov. Jim Pillen’s (R) Policy Research Office, the policy lobbying arm of the state’s chief executive.

No draft rules or regulations, including licensing criteria, have yet been made public.

Crista Eggers, executive director of Nebraskans for Medical Marijuana, which has led medical cannabis ballot measures since 2020, said she’s faced a lack of transparency and been unable to reach the commission or have questions answered in recent weeks, leaving many advocates “extremely frustrated.”

“I didn’t know we could be more frustrated than what we have been previously, but there just seems to be a new layer added every single day,” Eggers said Tuesday.

Keep reading

U.S. House Approves Amendment Allowing VA Doctors to Recommend Medical Cannabis to Veterans

The U.S. House of Representatives has approved an amendment that would allow Department of Veterans Affairs (VA) physicians to recommend medical marijuana to veterans in states where it’s legal.

The measure, introduced by Representatives Brian Mast (R-FL) and Dave Joyce (R-OH), was adopted as part of the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R. 3944). The overall bill is expected to receive a final vote on the House floor soon.

The amendment would prohibit the VA from using federal funds to enforce a longstanding policy that prevents VA doctors from assisting patients with enrolling in state-approved medical marijuana programs. Under current rules, VA physicians are barred from discussing or filling out the necessary paperwork for veterans to access legal marijuana, even in the 39 states that allow its use for medical purposes.

The amendment states:

“None of the funds appropriated or otherwise made available to the Department of Veterans Affairs in this Act may be used to enforce Veterans Health Directive 1315 as it relates to:

(1) the policy stating that ‘VHA providers are prohibited from completing forms or registering Veterans for participation in a State-approved marijuana program’;

(2) the directive for the ‘Deputy Under Secretary for Health for Operations and Management’ to ensure that ‘medical facility Directors are aware that it is VHA policy for providers to assess Veteran use of marijuana but providers are prohibited from recommending, making referrals to or completing paperwork for Veteran participation in State marijuana programs’; and

(3) the directive for the ‘VA Medical Facility Director’ to ensure that ‘VA facility staff are aware of the following’ ‘[t]he prohibition recommending, making referrals to or completing forms and registering Veterans for participation in State-approved marijuana programs.

Two bills have been filed this year in the House that would take a similar approach in easing access to medical cannabis for veterans, the Veterans Cannabis Use for Safe Healing Act and the Veterans Equal Access Act, filed by Rep. Gregory Steube (R-FL) and Brian Mast (R-FL).

Keep reading

Federal Court Upholds Arkansas Hemp Restrictions, Contradicting Texas Governor’s Stance In Vetoing Proposed Ban In His State

Several of the reasons Texas Gov. Greg Abbott (R) made for vetoing a statewide THC ban, SB 3, were rejected Tuesday by the Eighth Circuit Court of Appeals.

The Texas legislature overwhelmingly passed SB 3 with bipartisan support during the regular legislative session. Late Sunday night, Abbott vetoed it.

In his proclamation explaining the veto, he said SB 3 was “well-intentioned. But it would never go into effect because of valid constitutional challenges.” If it were enacted, “its enforcement would be enjoined for years, leaving existing abuses unaddressed,” he said, adding that “Texas cannot afford to wait.”

He pointed to Arkansas enacting a THC ban in 2023, Act 629, which was challenged in court. A lower court halted it from going into effect, arguing it would “likely [be] preempted by federal statutes and that its criminal provisions were likely unconstitutionally vague,” Abbott said. “The result in Arkansas? Their law has sat dormant, meaningless, having no effect for nearly two years while further legal proceedings play out. That result must be avoided in Texas,” Abbott said.

Instead, he proposed regulating THC similar to how alcohol is regulated.

On Monday, Patrick challenged each of Abbott’s arguments, saying they were flawed and factually inaccurate. Federal law expressly permits states to impose their own restrictions, including banning THC, Patrick said. He also said the Fourth and Seventh circuits have ruled as much and California and Colorado banned THC with no problems, The Center Square reported.

He said he believed the 8th Circuit would rule in favor of Arkansas.

One day later, it did.

On Tuesday, a panel of judges on the Eighth Circuit, including the chief judge, reversed the lower court’s injunction.

The judges also confirmed Patrick’s argument, stating in their 16-page ruling that nothing in the 2018 Farm Bill “preempts or limits any law of a State or Indian tribe that…regulates production of hemp and is more stringent than this subchapter.”

Keep reading

Rand Paul Files Bill To Triple Federal THC Limit For Hemp As House Pursues Crackdown On Consumable Cannabinoids

As the hemp industry raises concerns about congressional attempts to ban most consumable cannabinoid products, a GOP senator has filed a bill that would triple the concentration of THC that the crop could legally contain, while addressing multiple other concerns the industry has expressed about federal regulations.

Sen. Rand Paul (R-KY) introduced the legislation, titled the Hemp Economic Mobilization Plan (HEMP) Act, last week. It mirrors versions he’s sponsored over the last several sessions.

Hemp and its derivatives were legalized under the 2018 Farm Bill, but the industry has experienced multiple setbacks in the years since—and the proliferation of intoxicating cannabinoid products has led to pushes in Congress and state legislatures across the country to reign in the largely unregulated market.

To that point, a GOP-led House committee this week approved a spending bill containing provisions that hemp stakeholders say would devastate the industry, prohibiting most consumable cannabinoid products that were federally legalized during the first Trump administration.

The legislation would “effectively” criminalize hemp-derived cannabinoid products, including CBD, according to a Congressional Research Service (CRS) report.

In contrast, the newly reintroduced measure from Paul would address one of the most common complaints that lawmakers have heard from hemp businesses under the current law, which is that the crop is federally defined as containing no more than 0.3 percent THC by dry weight. They say that’s too low, and so the bill would increase that threshold to 1 percent.

It would also address potential problems with testing requirements under U.S. Department of Agriculture (USDA) regulations. Hemp processors currently get a 15-day window to test the crop’s flower to ensure that the THC concentration is within the allowed limits. But testing flower can be onerous and farmers have said it would stretch their resources thin, not to mention that the plant’s THC is significantly impacted by external factors.

To fix that issue, the bill calls for final hemp products themselves to be tested, rather than the initial flower from the plant.

Keep reading

Marijuana Industry Workers Are The Happiest In Any Job Sector In The U.S., Survey Finds

Hourly workers in the marijuana industry rank at the top of the list of “happiest” employees across multiple sectors—with more than 9 in 10 reporting a “positive sentiment” in their job—according to a new survey.

The annual Shift Pulse Report from the workforce management platform Deputy gauged how hourly workers felt about their jobs in 10 common industries—from cannabis to cleaning services to firearms.

While the overall finding of the report is that American workers are becoming less happy, with the happiness sentiment down to 78.5 percent in 2025 compared to 80 percent the prior year, the sector with the most content employees work at marijuana or e-cigarette/tobacco businesses.

A total of nearly 92 percent of cannabis and tobacco hourly workers said they feel positively about their jobs. By contrast, that sentiment is shared by 91 percent of hourly employees at catering, 90 percent in cafes, 90 percent of those in dentistry, 89 percent in gyms, 87 percent in firearms, 86 percent in sit-down restaurants, 84 percent in cleaning services and 83 percent in childcare.

“This may reflect stronger workplace culture and wage competitiveness in newer, regulated industries that prioritize employee retention as they scale rapidly,” Deputy said.

It’s also notable that cannabis sector hourly workers report higher levels of happiness in their trade considering that the industry faces unique challenges under federal prohibition, which has included an outsized risk of being targeted in robberies since many marijuana businesses operate in a largely cash-based environment.

“This year’s happiest industry sectors reveal a growing trend: purpose, predictability, and a sense of control over one’s workday matter just as much—if not more—than prestige or pay alone,” the report says. “For employers looking to improve sentiment, these industries offer practical lessons in team cohesion, autonomy, and culture-building.”

Keep reading